Scoop: CellProthera eyes $30M round for PhIII trial of cell therapy for heart attacks: #Jefferies23
15 Nov 2023
Cell TherapyPhase 3
CellProthera plans to raise around $30 million in its first major fundraise to help advance its lead regenerative cell therapy program for patients who have recently experienced heart attacks into registrational development, Endpoints News has learned.
“We want to do the Phase III trial in both the US and EU, so we expect we need to raise as much as we’ve raised to date over several tranches, but this time in a single shot,” CEO Matthieu de Kalbermatten told Endpoints on Tuesday at the annual Jefferies healthcare conference in London.
Preview
Source: EndPoints
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
SIGN UP
LOG IN
BECOME A PREMIUM SUBSCRIBER
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
-Drugs
-Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.